ORMP — Oramed Pharmaceuticals Balance Sheet
0.000.00%
- $171.80m
- $121.19m
- $2.00m
Annual balance sheet for Oramed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 4 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-Q | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 146 | 156 | 162 | 142 | 126 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 148 | 157 | 163 | 143 | 133 |
| Net Property, Plant And Equipment | 0.888 | 1.8 | 1.57 | 1.11 | 1.34 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 178 | 162 | 221 | 155 | 231 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.37 | 5.75 | 53.2 | 5.68 | 19.1 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.4 | 9.83 | 56.7 | 9.01 | 31.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 166 | 152 | 164 | 146 | 200 |
| Total Liabilities & Shareholders' Equity | 178 | 162 | 221 | 155 | 231 |
| Total Common Shares Outstanding |